Prognostic Role of Interleukin-6, Interleukin-8, and Leptin Levels According to Breast Cancer Subtype
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Inflammation within the tumor microenvironment has been reported to show an association with poor prognosis in breast cancer. However, the associations may differ according to breast cancer subtype. In this study, we investigated the association between inflammation-related markers and breast cancer recurrence according to patients’ tumor subtypes. Materials and Methods This prospective study included 240 patients who underwent surgery for management of newly diagnosed breast cancer. Levels of inflammation-related markers (interleukin [IL]-1β, IL-6, IL-8, monocyte chemoattractant protein-1 [MCP-1], leptin, and adiponectin)were measured at diagnosis, and the associations between these markers and breast cancer recurrence during a six-year follow-up period were examined using the Kaplan-Meier statistical method. Results Overall, inflammation-related markers showed no association with breast cancer recurrence. However, when data were stratified by tumor subtype, higher levels of some mediators showed an association with poor prognosis among patients with particular subtypes. Compared to patients without recurrence, patients with recurrence had higher levels of circulating IL-6 (p=0.024) and IL-8 (p=0.016) only among those with HER2– tumors and had higher levels of leptin (p=0.034) only among those with estrogen receptor (ER)+/progesterone receptor (PR)+ tumors. Results of survival analyses revealed an association of high levels of IL-6 (p=0.016) and IL-8 (p=0.022)with poor recurrence-free survival in patients with HER2– tumors. In addition, higher leptin levels indicated shorter recurrence-free survival time only among patients with ER+/PR+ tumors (p=0.022). Conclusion We found that certain cytokines could have a differential prognostic impact on breast cancer recurrence according to breast cancer subtype. Conduct of additional large studies will be required in order to elucidate the precise roles of these cytokines in breast cancer progression.
Abstract
Purpose Inflammation within the tumor microenvironment has been reported to show an association with poor prognosis in breast cancer. However, the associations may differ according to breast cancer subtype. In this study, we investigated the association between inflammation-related markers and breast cancer recurrence according to patients’ tumor subtypes. Materials and Methods This prospective study included 240 patients who underwent surgery for management of newly diagnosed breast cancer. Levels of inflammation-related markers (interleukin [IL]-1β, IL-6, IL-8, monocyte chemoattractant protein-1 [MCP-1], leptin, and adiponectin)were measured at diagnosis, and the associations between these markers and breast cancer recurrence during a six-year follow-up period were examined using the Kaplan-Meier statistical method. Results Overall, inflammation-related markers showed no association with breast cancer recurrence. However, when data were stratified by tumor subtype, higher levels of some mediators showed an association with poor prognosis among patients with particular subtypes. Compared to patients without recurrence, patients with recurrence had higher levels of circulating IL-6 (p=0.024) and IL-8 (p=0.016) only among those with HER2– tumors and had higher levels of leptin (p=0.034) only among those with estrogen receptor (ER)+/progesterone receptor (PR)+ tumors. Results of survival analyses revealed an association of high levels of IL-6 (p=0.016) and IL-8 (p=0.022)with poor recurrence-free survival in patients with HER2– tumors. In addition, higher leptin levels indicated shorter recurrence-free survival time only among patients with ER+/PR+ tumors (p=0.022). Conclusion We found that certain cytokines could have a differential prognostic impact on breast cancer recurrence according to breast cancer subtype. Conduct of additional large studies will be required in order to elucidate the precise roles of these cytokines in breast cancer progression.
참고문헌 (25)
- Goldberg JE, "Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics", Curr Drug Targets, 11, pp.1133~1146 (2010)
- Gilbert CA, "Cytokines, obesity, and cancer: new insights on mechanisms linking obesity to cancer risk and progression", Annu Rev Med, 64, pp.45~57 (2013)
- Nicolini A, "Cytokines in breast cancer", Cytokine Growth Factor Rev, 17, pp.325~337 (2006)
- Seruga B, "Cytokines and their relationship to the symptoms and outcome of cancer", Nat Rev Cancer, 8, pp.887~899 (2008)
- Onitilo AA, "Breast cancer subtypes based on ER", PR and Her2 expression: comparison of clinicopathologic features and survival, 2009, pp.7, 4~13
- Gonzalez RM, "Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased", Cancer Epidemiol Biomarkers Prev, 20, pp.1543~1551 (2011)
- Levano KS, "Breast cancer subtypes express distinct receptor repertoires for tumor-associated macrophage derived cytokines", Biochem Biophys Res Commun, 411, pp.107~110 (2011)
- McShane LM, "Reporting recommendations for tumor marker prognostic studies", J Clin Oncol, 23, pp.9067~9072 (2005)
- Regitnig P, "Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories", Virchows Arch, 441, pp.328~334 (2002)
- Jacobs TW, "Specificity of HercepTest in determining HER-2", neu status of breast cancers using the United States Food and Drug Administration- approved scoring system, 1999, pp.17, 1983~1987
- Nam BH, "Breast cancer subtypes and survival in patients with brain metastases", Breast Cancer Res, 10, pp.R20~ (2008)
- Yerushalmi R, "Ki67 in breast cancer: prognostic and predictive potentia", Lancet Oncol, 11, pp.174~183 (2010)
- Edge SB, "AJCC cancer staging manual", pp.347~376 (2010), Springer
- Henson DE, "Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index", Cancer, 68, pp.2142~2149 (1991)
- Cole SW, "Chronic inflammation and breast cancer recurrence", J Clin Oncol, 27, pp.3418~3419 (2009)
- Salgado R, "Circulating interleukin-6 predicts survival in patients with metastatic breast cancer", Int J Cancer, 103, pp.642~646 (2003)
- Bachelot T, "Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients", Br J Cancer, 88, pp.1721~1726 (2003)
- Benoy IH, "Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival", Clin Cancer Res, 10, pp.7157~7162 (2004)
- Muraro E, "A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immunebased therapies", Breast Cancer Res, 13, pp.R117~ (2011)
- Ciampricotti M, "Development of metastatic HER2(+) breast cancer is independent of the adaptive immune system", J Pathol, 224, pp.56~66 (2011)
- Barone I, "Leptin mediates tumor-stromal interactions that promote the invasive growth of breast cancer cells", Cancer Res, 72, pp.1416~1427 (2012)
- Catalano S, "Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line", J Biol Chem, 278, pp.28668~28676 (2003)
- Catalano S, "Leptin induces, via ERK1", ERK2 signal, functional activation of estrogen receptor alpha in MCF-7 cells, 2004, pp.279, 19908~19915
- Garofalo C, "Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli", Clin Cancer Res, 12, pp.1447~1453 (2006)
- Karczewska A, "Expression of interleukin-6, interleukin-6 receptor, and glycoprotein 130 correlates with good prognoses for patients with breast carcinoma", Cancer, 88, pp.2061~2071 (2000)